Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a world-class university medical institution that has achieved a global reputation for excellence in caring and curing, medical research, and education. It includes a tertiary University Hospital at Ein-Kerem and a community university hospital at Mt. Scopus, both in Jerusalem, Israel. Together with the Hebrew University, HMO owns and operates schools of medicine, nursing, dental medicine, public health, and occupational therapy. HMO’s medical centres treat all those who come within its doors and are in need of care without discrimination, regardless of their religion, nationality, race, gender or political beliefs. About one million patients are treated at HMO medical centres every year. HMO’s 5,000 employees work at its two campuses with more than 1,100 beds, over 100 sub-specialties, 31 operating rooms, 9 intensive care units, and more than 120 outpatient clinics.
In both hospitals and within most hospital departments, HMO’s physicians and scientists are actively engaged in an extensive variety of basic and clinical research projects, conducting more than half the medical research in the State of Israel and providing an important framework for clinical studies. HMO’s research results appear in prestigious professional journals with the highest number of research articles among all hospitals in Israel.
HMO is continuously engaged in biomedical research projects funded by the EU and is willing and fully equipped to support the goals of the AlternativesToGd proposal in terms of infrastructure, laboratory facilities, research staff, administration, and finance. The HMO Radiology department has pioneered many innovations in medical imaging, in MRI, body MRI, Neuroradiology, Interventional neuro/and radiology, CT, spectral CT, and radiofrequency ablation. The Centre for Hyperpolarised MRI Molecular Imaging is situated within the MRI institute at the Department of Radiology and enjoys a special and productive mix of clinical work with basic science. This Centre was established 10 years ago with the mission to advance hyperpolarised molecular imaging probes for clinical use and provide new and improved diagnoses.
Role in project
HMO will be the Project Coordinator and perform studies with hyperpolarised substrates in vitro and in vivo. HMO will be the leader for WP1 and a partner on WP2 and WP5. In WP1, HMO will focus on hyperpolarised probes developed as perfusion and tissue-retention agents, further